Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs)

Kristof Chwalisz, Ramesh Garg, Robert Brenner, Ov Slayden, Craig Winkel, Walter Elger

    Research output: Contribution to journalReview article

    23 Scopus citations

    Abstract

    Selective progesterone receptor modulators (SPRMs) represent a new class of progesterone receptor ligands that exert clinically relevant tissue-selective progesterone agonist, antagonist, partial, or mixed agonist/antagonist effects on various progesterone target tissues in an in vivo situation depending on the biological action studied. The SPRM asoprisnil is being studied in women with symptomatic uterine leiomyomata and endometriosis. Asoprisnil shows a high degree of uterine selectivity as compared to effects on ovulation or ovarian hormone secretion in humans. It induces amenorrhea and decreases leiomyoma volume in a dose-dependent manner in the presence of follicular phase estrogen concentrations. It also has endometrial antiproliferative effects. In pregnant animals, the myometrial, i.e. labor-inducing, effects of asoprisnil are blunted or absent. Studies in non-human primates played a key role during the preclinical development of selective progesterone receptor modulators. These studies provided the first evidence of uterus-selective effects of asoprisnil and structurally related compounds, and the rationale for clinical development of asoprisnil.

    Original languageEnglish (US)
    Article numberS8
    JournalReproductive Biology and Endocrinology
    Volume4
    Issue numberSUPPL. 1
    DOIs
    StatePublished - Oct 9 2006

    ASJC Scopus subject areas

    • Reproductive Medicine
    • Endocrinology
    • Obstetrics and Gynecology
    • Developmental Biology

    Fingerprint Dive into the research topics of 'Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs)'. Together they form a unique fingerprint.

  • Cite this